Skip to main content
Evidence Snapshot

Serotonin (5-HT) receptor

CHEMBL2096904 PROTEIN FAMILY Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:44Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2096904
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serotonin (5-HT) receptor as ChEMBL target CHEMBL2096904, mapped to UniProt P30939. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serotonin (5-HT) receptor
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2096904
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30939
5-hydroxytryptamine receptor 1F
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Serotonin (5-HT) receptor matters

As of 2026-09-13

Serotonin (5-HT) receptor is reviewed as 5-hydroxytryptamine receptor 1F (UniProt P30939); Serotonin (5-HT) receptor shows approved-linked disease relevance led by Nausea and vomiting. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 50 compounds, and 35 assays, with lead potency reaching pChEMBL 9.8.

Protein context
5-hydroxytryptamine receptor 1F

5-hydroxytryptamine receptor 1F Sequence length is 366 aa.

Review this target as Serotonin (5-HT) receptor, mapped to UniProt P30939. ChEMBL maps the protein component as 5-hydroxytryptamine receptor 1F. Sequence length is 366 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P30939 Protein
Disease context
Nausea and vomiting

Serotonin (5-HT) receptor shows approved-linked disease relevance led by Nausea and vomiting. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMISULPRIDE.

Start review with Nausea and vomiting because it currently carries approved-linked support. Linked drugs include AMISULPRIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 50 compounds, and 35 assays for this target. The dominant activity type is IC50. CHEMBL323208 is the current potency anchor at pChEMBL 9.8.

Use CHEMBL323208 as the tractability anchor when discussing potency (pChEMBL 9.8).

Activity source · ChEMBL 36 via Core Engine
2 approved pChEMBL 9.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Serotonin (5-HT) receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P30939, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Nausea and vomiting is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

50
Total Compounds
35
Total Assays
2
Approved Drugs
IC50: 17.0, KI: 3.0, KD: 5.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL323208
9.8 Kd
9.0 IC50 Approved
9.0 Ki Approved
7.1 Kd Clinical
6.0 IC50

Approved Drugs

Structure Compound First Approval
IMIPRAMINE
CHEMBL11
1959
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:44Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2096904